IL-38 alleviates atherogenic responses via SIRT6/HO-1 signaling: A promising strategy against obesity-related atherosclerosis
- Authors
- Cho, Wonjun; Oh, Heeseung; Abd El-Aty, A.M.; Mobarak, Enas H.; Jeong, Ji Hoon; Jung, Tae Woo
- Issue Date
- Jan-2024
- Publisher
- Elsevier B.V.
- Keywords
- Atherosclerosis; HO-1; HUVEC; IL-38; SIRT6; THP-1
- Citation
- Biochemical and Biophysical Research Communications, v.694
- Journal Title
- Biochemical and Biophysical Research Communications
- Volume
- 694
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/72684
- DOI
- 10.1016/j.bbrc.2023.149407
- ISSN
- 0006-291X
1090-2104
- Abstract
- Interleukin-38 (IL-38), a member of the IL-1 family, is known for its anti-inflammatory properties mediated through ligand signaling in various disease models. It plays a significant role in atherosclerosis development, forming a theoretical basis for therapeutic strategies. However, the direct effects of IL-38 on atherogenic responses in the vascular endothelium and monocytes remain unclear. In this investigation, IL-38 treatment reduced THP-1 monocyte adhesion to HUVECs, decreased the expression of vascular adhesion molecules, and mitigated inflammation in the presence of palmitate. IL-38 treatment upregulated SIRT6 expression and enhanced autophagy markers such as LC3 conversion and p62 degradation. The effects of IL-38 were nullified by siRNA-mediated suppression of SIRT6 or heme oxygenase-1 (HO-1) in HUVECs and palmitate-treated THP-1 cells. These findings reveal that IL-38 mitigates inflammation through the SIRT6/HO-1 pathway, offering a potential therapeutic approach for addressing obesity-related atherosclerosis. © 2023 Elsevier Inc.
- Files in This Item
-
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.